Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...

Here’s what you’ll learn when you read this story: We are generating staggering amounts of data every day. Data centers just can’t keep up with the demand. With data storage needs expected to soar in ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Holdings sells 155 million Convatec shares at 5.1% discount Sale marks Novo's exit from Convatec Convatec shares fall as much as 4.3% Shares in Convatec fell as much as 4.3% to 228.8 pence per ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

“The laws of inheritance are quite unknown,” Charles Darwin acknowledged in 1859. The discovery of DNA’s shape altered how we conceived of life itself. The X-ray crystallography by Rosalind Franklin ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying shares in the drugmaker for almost 15 years. Michael Novod, one the best known ...

Novo Nordisk NOVO B announced plans on Oct. 9 to acquire Akero Therapeutics and its phase 3 FGF21 analog efruxifermin for USD 4.7 billion upfront and a potential additional USD 500 million contingent ...